CClinicalTrials.gg
Sign In
Status unknownNCT04396158Updated May 27, 2020

Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

An interventional study of radioactive iodine in Ovarian Insufficiency and Radiation Exposure, sponsored by Assiut University. Status unknown. Open to female participants aged 15 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Assiut University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
15 Years to 45 Years
Sex
Female
01

Study summary

Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.

02

Conditions studied

  • Ovarian Insufficiency
  • Radiation Exposure

Browse trials for

03

In context

Thyroid Neoplasms

802 studies on the registry are indexed under Thyroid Neoplasms; 216 are open to participants now.

This study's planned enrollment of 38 is below the median of 51 across 507 interventional studies indexed under Thyroid Neoplasms.

Browse Thyroid Neoplasms studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female patient in childbearing period.
  • Female patient with differentiated thyroid carcinoma.
  • Underwent thyroidectomy.
  • Candidate for radioactive iodine therapy.

Exclusion criteria

Exclusion Criteria:

    • Male patients.

      • Postmenopausal female patients.
      • Female patients with undifferentiated thyroid carcinoma.
      • Pregnant female patients.
      • Lactating female patients.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    intervention

    Radiation: radioactive iodine

Interventions

  • Radiationradioactive iodine

    80-200 mCi of radioactive iodine will be given to thyroid cancer patients

06

What researchers measure

Primary outcomes

  1. Level of anti-Müllerian (AMH) hormone

    Level of anti-Müllerian (AMH) hormone in female patients before and after radioactive iodine therapy.

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04396158
Lead sponsor
Assiut University
Responsible party
Hebat Allah Ahmed Askar (Lecturer of nuclear medicine, Assiut University) — Principal investigator
First posted
May 20, 2020
Start date
Jun 15, 2020 (estimated)
Primary completion
Jun 15, 2021 (estimated)
Completion
Dec 15, 2021 (estimated)
Last update
May 27, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thyroid Neoplasms→

Other studies from this sponsor

Assiut University

Start the discussion